Achilles Therapeutics plc (NASDAQ:ACHL - Get Free Report) was the recipient of a significant drop in short interest in February. As of February 28th, there was short interest totalling 478,300 shares, a drop of 40.1% from the February 13th total of 797,900 shares. Based on an average daily trading volume, of 1,070,000 shares, the short-interest ratio is presently 0.4 days. Approximately 1.3% of the shares of the stock are sold short.
Achilles Therapeutics Stock Up 3.5 %
NASDAQ:ACHL traded up $0.05 during trading hours on Tuesday, reaching $1.49. 764,636 shares of the company's stock were exchanged, compared to its average volume of 538,563. The company has a market capitalization of $61.24 million, a P/E ratio of -0.90 and a beta of 1.25. Achilles Therapeutics has a 12 month low of $0.63 and a 12 month high of $1.51. The business's 50-day simple moving average is $1.29 and its two-hundred day simple moving average is $1.09.
Institutional Trading of Achilles Therapeutics
A number of large investors have recently added to or reduced their stakes in ACHL. XTX Topco Ltd bought a new stake in Achilles Therapeutics during the fourth quarter worth approximately $31,000. Two Sigma Advisers LP boosted its stake in Achilles Therapeutics by 52.7% in the 4th quarter. Two Sigma Advisers LP now owns 34,200 shares of the company's stock worth $39,000 after purchasing an additional 11,800 shares during the period. BNP Paribas Financial Markets acquired a new position in Achilles Therapeutics in the 4th quarter worth approximately $57,000. Finally, Two Sigma Investments LP boosted its stake in Achilles Therapeutics by 190.1% in the 4th quarter. Two Sigma Investments LP now owns 61,637 shares of the company's stock worth $70,000 after purchasing an additional 40,388 shares during the period. 56.38% of the stock is currently owned by institutional investors.
About Achilles Therapeutics
(
Get Free Report)
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.
See Also
Before you consider Achilles Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Achilles Therapeutics wasn't on the list.
While Achilles Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
